dr. schmid on benefit of pembrolizumab in patients with tnbc
Published 4 years ago • 251 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:06
dr. schmid on the design and findings of the keynote-173 trial in tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
24:01
the role of immunotherapy in advanced tnbc prof. peter schmid
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
1:46
dr. schmid discusses the findings of impassion130 in tnbc
-
27:45
treatment options for triple-negative breast cancer prof. peter schmid
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
21:00
precision medicine in metastatic triple negative breast cancer
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
8:32
immunotherapy for triple-negative breast cancer
-
1:06
dr. tolaney on pembrolizumab plus eribulin in tnbc
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer